What is the difference between Orforglipron and Semaglutide?

Orforglipron is classified as: Oral small-molecule (non-peptide) agonist of the glucagon-like peptide-1 (GLP-1) receptor. Semaglutide is classified as: Glucagon-like peptide-1 (GLP-1) receptor agonist. Orforglipron is approved for one or more medical uses in at least one major jurisdiction. Semaglutide is approved for one or more medical uses in at least one major jurisdiction.

Is Orforglipron or Semaglutide approved?

Orforglipron is approved for one or more medical uses in at least one major jurisdiction. Semaglutide is approved for one or more medical uses in at least one major jurisdiction. Regulatory status by region is set out in the table above.

How much clinical trial evidence is tracked for Orforglipron and Semaglutide?

Peptide Science Daily tracks 49 registered clinical trials for Orforglipron (evidence grade B) and 500 for Semaglutide (evidence grade A).

Compound comparison

Orforglipron vs Semaglutide

This page sets Orforglipron and Semaglutide side by side using the data recorded on Peptide Science Daily: drug class, mechanism of action, regulatory status by region, the evidence grade assigned here, and the number of clinical trials tracked. It is a neutral, factual comparison and does not rank either compound or recommend one over the other.

Side-by-side comparison

Class: Orforglipron
Oral small-molecule (non-peptide) agonist of the glucagon-like peptide-1 (GLP-1) receptor
Semaglutide
Glucagon-like peptide-1 (GLP-1) receptor agonist
Mechanism: Orforglipron
In plain terms, orforglipron is a pill that mimics the gut hormone GLP-1, which lowers blood sugar and reduces appetite.
Semaglutide
In plain terms, semaglutide copies a natural gut hormone that signals fullness and helps control blood sugar.
United States (FDA): Orforglipron
Approved. The FDA approved orforglipron (Foundayo) on April 1, 2026 for chronic weight management in adults with obesity, or overweight with weight-related conditions, based on the ATTAIN Phase 3 program. A type 2 diabetes indication (ACHIEVE program) is not yet approved.
Semaglutide
Approved. Ozempic for type 2 diabetes (2017, cardiovascular risk reduction added 2020); Rybelsus oral for type 2 diabetes (2019); Wegovy for chronic weight management (2021) and cardiovascular risk reduction (2024); oral Wegovy for weight management approved in 2025.
European Union (EMA): Orforglipron
Not authorized; no marketing authorization at this time.
Semaglutide
Authorized - Ozempic and Rybelsus for type 2 diabetes and Wegovy for weight management.
Australia (TGA): Orforglipron
Not entered on the Australian Register of Therapeutic Goods (ARTG); not yet approved for supply.
Semaglutide
Registered on the ARTG - Ozempic for type 2 diabetes and Wegovy for weight management, available on prescription.
WADA: Orforglipron
Not listed on the WADA Prohibited List. As a GLP-1 receptor agonist it is not a banned substance.
Semaglutide
Not prohibited. On the WADA Monitoring Program (introduced 2024, continued into 2026); it is tracked but not a banned substance.
Evidence grade: Orforglipron
B
Semaglutide
A
Tracked clinical trials: Orforglipron
49
Semaglutide
500
Full profile: Orforglipron
Orforglipron profile
Semaglutide
Semaglutide profile

Comparison of Orforglipron and Semaglutide by class, mechanism, regulatory status by region, evidence grade, and number of tracked clinical trials.
Attribute	Orforglipron	Semaglutide
Class	Oral small-molecule (non-peptide) agonist of the glucagon-like peptide-1 (GLP-1) receptor	Glucagon-like peptide-1 (GLP-1) receptor agonist
Mechanism	In plain terms, orforglipron is a pill that mimics the gut hormone GLP-1, which lowers blood sugar and reduces appetite.	In plain terms, semaglutide copies a natural gut hormone that signals fullness and helps control blood sugar.
United States (FDA)	Approved. The FDA approved orforglipron (Foundayo) on April 1, 2026 for chronic weight management in adults with obesity, or overweight with weight-related conditions, based on the ATTAIN Phase 3 program. A type 2 diabetes indication (ACHIEVE program) is not yet approved.	Approved. Ozempic for type 2 diabetes (2017, cardiovascular risk reduction added 2020); Rybelsus oral for type 2 diabetes (2019); Wegovy for chronic weight management (2021) and cardiovascular risk reduction (2024); oral Wegovy for weight management approved in 2025.
European Union (EMA)	Not authorized; no marketing authorization at this time.	Authorized - Ozempic and Rybelsus for type 2 diabetes and Wegovy for weight management.
Australia (TGA)	Not entered on the Australian Register of Therapeutic Goods (ARTG); not yet approved for supply.	Registered on the ARTG - Ozempic for type 2 diabetes and Wegovy for weight management, available on prescription.
WADA	Not listed on the WADA Prohibited List. As a GLP-1 receptor agonist it is not a banned substance.	Not prohibited. On the WADA Monitoring Program (introduced 2024, continued into 2026); it is tracked but not a banned substance.
Evidence grade	B	A
Tracked clinical trials	49	500
Full profile	Orforglipron profile	Semaglutide profile

Common questions

What is the difference between Orforglipron and Semaglutide?: Orforglipron is classified as: Oral small-molecule (non-peptide) agonist of the glucagon-like peptide-1 (GLP-1) receptor. Semaglutide is classified as: Glucagon-like peptide-1 (GLP-1) receptor agonist. Orforglipron is approved for one or more medical uses in at least one major jurisdiction. Semaglutide is approved for one or more medical uses in at least one major jurisdiction.
Is Orforglipron or Semaglutide approved?: Orforglipron is approved for one or more medical uses in at least one major jurisdiction. Semaglutide is approved for one or more medical uses in at least one major jurisdiction. Regulatory status by region is set out in the table above.
How much clinical trial evidence is tracked for Orforglipron and Semaglutide?: Peptide Science Daily tracks 49 registered clinical trials for Orforglipron (evidence grade B) and 500 for Semaglutide (evidence grade A).